MetaCap

NervGen Pharma Corp. (NGEN)

NASDAQ: NGENHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.85-0.075 (-3.91%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NGEN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$198.55M
EPS (TTM)
-$0.24
52-week range
1.28 – 6.30
Day range
1.83 – 1.96
Volume / Avg
661.48K / 621.66K
Beta
—

52-week range

$1.28$6.30

NGEN stock today

Shares of NervGen Pharma (NGEN) finished lower on Nov 20 at $1.85, a drop of 3.91% or $0.075 per share, versus the S&P 500's 3.70% decline. At this level, NGEN sits near the bottom of its 52-week range of $1.28 to $6.30: 70.7% below the high, set on Jan 8, 2026 and 44.1% above the low. NGEN is down 67.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.0%.

NervGen Pharma has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NervGen Pharma

Company profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Adam H. Rogers M.D.
Headquarters
Vancouver, BC
Employees
9

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$10.00+442.01%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.04 vs $0.01
Surprise
-500.00%

NGEN news

All NGEN news

NervGen Pharma peers

Health Care sector
NGEN peer companies
CompanyPrice% ChgMarket capCompare
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs NGEN
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs NGEN
DRUGBright Minds Biosciences Inc.20.40-1.45%$201.23Mvs NGEN
ACIUAC Immune SA1.95-8.45%$193.88Mvs NGEN
BCYCBicycle Therapeutics plc ADR2.90-4.92%$203.27Mvs NGEN
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs NGEN
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs NGEN
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs NGEN

Indexes, lists and sector

NervGen Pharma stock FAQ

What is NervGen Pharma's stock price today?

NGEN last traded at $1.85 as of Nov 20, 4:00 PM EST, down 3.91% on the day. Prices are delayed at least 15 minutes.

Who is NervGen Pharma's CEO?

Dr. Adam H. Rogers M.D. is the chief executive officer of NervGen Pharma Corp., which has about 9 employees.

What is the NGEN 52-week high?

The 52-week high for NGEN is $6.30 and the 52-week low is $1.28. The stock is currently 70.7% below its high.

Compare NGEN